Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Severity addiction

Methamphetamine use

Estimated Enrollment:

150

Study Start Date:

July 2003

Estimated Study Completion Date:

June 2005

Detailed Description:

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Eligibility

Ages Eligible for Study:

18 Years to 65 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00069251